BRAF and melanoma: A similar effect was shown by Boisvert-Adamo and Aplin: they bypassed the resistance conferred by hyper-activated MAPK and PI3K signaling pathways and enhanced apoptosis by treating BRAF-silenced melanoma cells with LY294002 (81).